Tadalafil topical - Callitas Therapeutics

Drug Profile

Tadalafil topical - Callitas Therapeutics

Alternative Names: Extrinsa

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Callitas Therapeutics
  • Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Indoles; Pyridones; Small molecules; Vasodilators
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Female sexual dysfunction

Most Recent Events

  • 01 Nov 2017 Callitas Therapeutics receive a successful response from the US Food and Drug Administration in its Pre-IND Meeting Request Written Response for Tadalafil topical for the treatment of Female sexual dysfunction
  • 11 Oct 2017 Callitas Therapeutics plans to initiate clinical trials for Female sexual dysfunction in the first quarter of 2018
  • 18 Jul 2017 Preclinical trials in Female sexual dysfunction in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top